The need for agents designed to modify immune response in the treatment of patients with viral infection, immunodeficiency, or cancer prompted the present study on the mechanisms of action of isoprinosine, a compound developed for antiviral use and whose therapeutic activity may involve the immune system. The effect of isoprinosine on in vitro proliferation of human peripheral blood lymphocytes stimulated by phytohemagglutinin (PHA) and on lymphocyte levels of cyclic adenosine 3' ,5'-monophosphate and cyclic guanosine 3' ,5'-monophosphate was analyzed. Over a concentration range from 0.2 to 250 ug/ml, isoprinosine augmented PHA-induced proliferation; maximal stimulation was observed between 25 to 50 ,ug/ml. Isoprinosine in the absence of PHA had no effect on proliferation. The relative lack of effect of isoprinosine during a 90-min exposure and the lack of effect on lymphocyte cyclic nucleotide levels indicate that isoprinosine potentiates the PHA response by a mechanism different than a number of hormonal agents and such immunopotentiators as levamisole, polyadenylic-acid, and endotoxin. Further evaluation of isoprinosine as an immunopotentiator is indicated.
A clinical need exists for therapeutic agents designed to augment immune response in the treatment of patients with deficient or depressed resistance mechanisms. A number of immunopotentiators are under study for possible clinical use in patients with immunodeficiency, cancer, and viral infections (see reference 11 for review). Of the agents currently available for systemic viral infections, a number, including iododeoxyuridine (2) and cytosine arabinoside (20) , have significant side effects resulting in suppression of host immune response; these side effects clearly limit the effectiveness of these agents (12) . Since cellular immune response and interferon are thought to be central in the defense against most if not all virus infections, considerable current research attention has been focused on agents that augment cellular immune response (i.e., transfer factor, levamisole, polynucleotides, and bacterial adjuvants such as BCG) and induce or augment interferon-related mechanisms (e.g., exogenous interferon, polynucleotides, tilerones, and statalon).
One agent having reported antiviral effects (see reference 4 for review) is isoprinosine, the p-acetamidobenzoic acid salt of inosine dimethylamino-isopropanol (1:3 molar ratio). This compound has been shown in several clinical studies to produce a degree of enhancement of serum antibody response in patients with viral respiratory illness secondary to influenza or rhinovirus. With reference to cellular immune response, the effects of this agent to protect hamsters (5) and mice (4) from herpesvirus and influenza virus, respectively, are dependent upon mechanisms suppressed by antilymphocyte globulin or cortisone acetate, two wellknown suppressants of cellular immune response. These experimental data suggest that the in vivo antiviral effects of isoprinosine may depend, in part, on an action to augment cellular as well as humoral immune response. The present study analyzes the effects of isoprinosine on an in vitro assay of the proliferative response of human peripheral blood lymphocytes stimulated by phytohemagglutinin (PHA) and demonstrates that isoprinosine significantly augments mitogen-induced lymphocyte proliferation. Analysis of the effects of isoprinosine on lymphocyte cyclic nucleotide levels indicates that, unlike a number of immunopotentiating influences, isoprinosine does not augment lymphocyte transformation through a direct action on these cyclic nucleotide regulatory pathways. MATERIALS , and thymidine incorporation was assayed by liquid scintillation spectrometry. Cultures were performed in triplicate, and the data are presented as the averaged means of several different individual experiments plus or minus the standard error of the experimental means. Error terms, therefore, express interindividual variation rather than intraexperiment variation (<5% for triplicates).
Cyclic nucleotide measurements. Lymphocytes (10 x 101) were suspended in 1 ml of Hanks balanced salt solution in plastic Falcon tubes (12 by 117 mm). Lymphocytes were allowed to equilibrate for 1 h at 37 C. The experimental compounds were added in microliter volumes for various times, followed by termination with 0.5 ml of cold 30% trichloroacetic acid. Samples were frozen in dry ice and stored at -20 C. Samples were thawed, and 0.01 JACi of [3H]cyclic guanosine 3',5'-monophosphate (cGMP) (New England Nuclear) was added to determine recovery of each sample. Protein was removed by centrifugation and determined by the method of Lowry et al. (14) . Trichloroacetic acid was removed from the supernatant by five extractions with 2 volumes of ether. Cyclic adenosine 3',5'-monophosphate (cAMP) and cGMP were purified according to the protocol of Goldberg and Haddox (personal communication), involving sequential column separation with Dowex-1-formate (15) and prostaglandin E, (PGE,; a gift from J. Pike, Upjohn Co., Kalamazoo, Mich.) were employed in these experiments to increase levels of cGMP and cAMP, respectively.
RESULTS
Effect of isoprinosine on PHA-induced lymphocyte proliferation. When isoprinosine was added to lymphocyte cultures in the absence of PHA, no effect on basal thymidine incorporation was observed. In the presence of an optimal mitogenic concentration of PHA (5 mU/ ml), isoprinosine over a concentration range from 0.2 to 250 ,u/ml augmented the PHA-induced proliferation (Fig. 1) . At a concentration of 500 A/ml isoprinosine had a variable effect:
in the presence of an optimal concentration of PHA no stimulation occurred; however, in the presence of a supraoptimal concentration of PHA (10 mU/ml) inhibition resulted (data not shown). Over the concentration range of 0.2 to 250 ,g/ml, isoprinosine stimulated PHA-induced proliferation in all individuals tested and peak stimulation averaged more than 50%o greater than the PHA control. A double-peaked dose-response curve was observed, with peaks of stimulation at 1 and 50 jig/ml. Figure 2 represents a further characterization of the effect of low concentrations of isoprinosine to augment the response of lymphocytes at three concentrations of PHA (2.5, 5, and 10 mU/ml). Whereas low concentrations of isoprinosine augmented PHA response at all three concentrations, its effects were greatest at optimal PHA concentrations (5 mU/ml). The (ii) Cyclic nucleotide levels. Based upon recent observations that implicate the cyclic nucleotides as major biochemical pathways involved in the regulation of lymphocyte proliferative responses (cf. 9), the effects ofisoprinosine on lymphocyte cyclic nucleotide levels were determined. A direct action on basal levels and an indirect one on the ability of other agonists to increase basal levels were measured to rule out effects either to stimulate the cyclic nucleotide cyclases or phosphodiesterases, respectively. Tables 1 and 2 show the results of two such experiments. No effects of isoprinosine at 2, 20, and 200 ,g/ml were observed on basal levels of cGMP or cAMP or on acetylcholine or prostaglandin PGE,-induced changes in these levels after a 1-h preincubation with 200 ,ug/ml. These experiments serve to exclude an effect of isoprinosine directly upon cyclic nucleotide generation or catabolism; however, they do not exclude an interaction with the cyclic nucleotides at the effector level. DISCUSSION PHA-induced lymphocyte proliferation has provided a widely used technique for estimating immunocompetence of the cellular immune system and for studying the early events of lymphocyte activation. PHA induces prolifera- tion of both T and B lymphocytes in human peripheral blood; however, the response of B lymphocytes to PHA in this system appears to be directly dependent upon, and in direct proportion to, T lymphocyte proliferation (7 The rationale for examining isoprinosine within the perspective of cyclic nucleotide action in lymphocytes is provided by those observations that indicate that the initiation of lymphocyte proliferation involves cGMP, is augmented by humoral agents that increase lymphocyte levels of cGMP and inhibited by those that increase levels of cAMP. In contrast, proliferation once initiated is facilitated by agents that increase levels of cyclic AMP (see 8, 9 for review). A number of immunopotentiating agents shown to be active in vivo, including lipopolysaccharide (1, 17) , levamisole (8a, 23), and polyadenylic acid-polyuridylic acid (6, 22) augment mitogen-induced lymphocyte proliferation in vitro and have been linked to cyclic nucleotides in their actions. These present experiments indicate the action of isoprinosine is different from these immunopotentiating agents and suggest that such action may be complementary to these agents, thus providing the basis for combined drug studies.
The present experiments demonstrate that isoprinosine has direct effects upon the in vitro proliferation of lymphocytes. Taken in conjunction with the evidence cited indicating effects in vivo upon immune response, they suggest that the further evaluation of the action of isoprinosine as an immunopotentiator, alone and in combination with other agents, is warranted.
